scholarly journals Elimination of blinding trachoma in China: why is further study necessary?

2016 ◽  
Vol 59 (6) ◽  
pp. 539-540 ◽  
Author(s):  
Ningli Wang
Keyword(s):  
Blinding Trachoma

Sensitivity analysis on the SEIR-SEI model for the dynamics of blinding trachoma

2021 ◽  
Author(s):  
Salisu M. Muhammad ◽  
Evren Hincal ◽  
Bilgen Kaymakamzade ◽  
Nezihal Gokbulut
Keyword(s):  
Sensitivity Analysis ◽  
Sei Model ◽  
Blinding Trachoma

The possibility of eliminating blinding trachoma

2003 ◽  
Vol 3 (11) ◽  
pp. 728-734 ◽  
Author(s):  
Jeffrey W Mecaskey ◽  
Charles A Knirsch ◽  
Jacob A Kumaresan ◽  
Joseph A Cook
Keyword(s):  
Blinding Trachoma

Eliminating Blinding Trachoma

2008 ◽  
Vol 358 (17) ◽  
pp. 1777-1779 ◽  
Author(s):  
Joseph A. Cook
Keyword(s):  
Blinding Trachoma

No blinding trachoma in Guangxi, China

2016 ◽  
Vol 1 ◽  
pp. 23-23
Author(s):  
Hao Liang ◽  
Hui-Yi Zuo ◽  
Yi Du ◽  
Lin-Zhi Jiang ◽  
Shao-Jian Tan
Keyword(s):  
Blinding Trachoma

scholarly journals Blinding trachoma: the forgotten problem

2001 ◽  
Vol 85 (12) ◽  
pp. 1397-1399 ◽  
Author(s):  
K. F TABBARA
Keyword(s):  
Blinding Trachoma

Blinding Trachoma in Katsina State, Nigeria: Population-Based Prevalence Survey in Ten Local Government Areas

2008 ◽  
Vol 15 (5) ◽  
pp. 294-302 ◽  
Author(s):  
Nimzing F. Jip ◽  
Jonathan D. King ◽  
Mamadou O. Diallo ◽  
Emmanuel S. Miri ◽  
Ahmed T. Hamza ◽  
...  
Keyword(s):  
Local Government ◽  
Population Based ◽  
Prevalence Survey ◽  
Blinding Trachoma

scholarly journals Antibiotic Resistance inStreptococcus pneumoniaeafter Azithromycin Distribution for Trachoma

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Derek K-H. Ho ◽  
Christian Sawicki ◽  
Nicholas Grassly
Keyword(s):  
Antibiotic Resistance ◽  
Web Of Science ◽  
Macrolide Antibiotic ◽  
Control Strategies ◽  
Risk Of Bias ◽  
Community Settings ◽  
Inclusion Criteria ◽  
Potential Sources ◽  
Blinding Trachoma

Trachoma is caused byChlamydia trachomatisand is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM inC. trachomatishas not been reported, there have been concerns about resistance in other organisms when AZM is administered in community settings. We identified studies that measured pneumococcal prevalence and resistance to AZM following mass AZM provision reported up to 2013 in Medline and Web of Science databases. Potential sources of bias were assessed using the Cochrane Risk of Bias Tool. A total of 45 records were screened, of which 8 met the inclusion criteria. We identified two distinct trends of resistance prevalence, which are dependent on frequency of AZM provision and baseline prevalence of resistance. We also demonstrated strong correlation between the prevalence of resistance at baseline and at 2-3 months (r=0.759). Although resistance to AZM inC. trachomatishas not been reported, resistance to this commonly used macrolide antibiotic in other diseases could compromise treatment. This should be considered when planning long-term trachoma control strategies.

Sign in / Sign up

Export Citation Format

Share Document